{"id":"W2015378165","doi":"10.1097/01.jto.0000283154.03863.ae","title":"B3-02: Randomized, double-blind, multicenter, parallel-group, Phase II study of gefitinib (IRESSA) plus best supportive care (BSC) versus placebo plus BSC in chemotherapy-naïve patients with advanced non-small-cell lung cancer and poor performance status (INSTEP)","year":2007,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"ca_institutions":"AstraZeneca (Canada); Regional Municipality of Durham; Ottawa Hospital","funders":"","keywords":"Medicine; Gefitinib; Chemotherapy; Lung cancer; Internal medicine; Oncology; Performance status; Placebo; Randomized controlled trial; Cancer; Epidermal growth factor receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002095943,0.003532132,0.006266273,0.0007615551,0.0008426367,0.001667708,0.002179644,0.003205145,0.01034673],"category_scores_gemma":[0.001768913,0.001356884,0.002173946,0.000685825,0.002262457,0.001952559,0.0005355071,0.005411066,0.002699014],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001063757,"about_ca_system_score_gemma":0.002425266,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002189177,"about_ca_topic_score_gemma":0.003741068,"domain_scores_codex":[0.999432,0.0002307693,0.00002879132,0.0001238753,0.00003959921,0.000144964],"domain_scores_gemma":[0.9990336,0.0001657803,0.0001583944,0.00008891775,0.0000581944,0.0004951418],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9837778,0.006633549,0.000157824,0.0002283731,0.0003468637,0.00001670239,0.00002551577,0.0002034257,0.001950429,0.00007244996,0.0008510549,0.005736122],"study_design_scores_gemma":[0.9821182,0.01704292,0.0002699695,0.000004902303,0.00008527641,0.00001003879,0.000005838242,0.0001364738,0.0001308143,0.00004586181,0.0001429718,0.000006696067],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.976375,0.003458588,0.001325078,0.001688938,0.001178638,0.008540753,0.003368251,0.0007844618,0.003280289],"genre_scores_gemma":[0.9659796,0.002530247,0.003895437,0.003196445,0.0008615463,0.01352793,0.00321708,0.0001514363,0.006640384],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01034673,"threshold_uncertainty_score":0.03461331,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02123277751310997,"score_gpt":0.4163424731809137,"score_spread":0.3951096956678037,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}